phosphorylcholine has been researched along with Brain Neoplasms in 42 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 7.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 7.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| "Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study." | 7.79 | Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy. ( Banerjee, R; Joshi, N; Shanmugam, T; Thakur, A, 2013) |
| "ErPC (40 mg/kg) was given to C6 glioma-bearing rats either as a single intracarotid bolus injection in the presence or absence of 1- O-pentylglycerol (300 m M) or as an intracarotid infusion in conjunction with bradykinin." | 7.71 | Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M, 2002) |
| "In the present study we investigate the effect of exogenous sphingosine, sphingosine 1-phosphate and sphingosylphosphorylcholine on phospholipase D (PLD) activity in glioma C6 cells." | 7.70 | Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells. ( Barańska, J; Bobeszko, M; Dygas, A; Sidorko, M, 1999) |
| "The effect of sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate on L-[U-14C]serine incorporation into phosphatidylserine and phosphatidylserine-derived phosphatidylethanolamine was investigated in intact glioma C6 cells." | 7.70 | Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells. ( Barańska, J; Wójcik, M, 1999) |
| "Perifosine was fixed as a 600 mg load on day 1 followed by 100 mg nightly (single agent MTD) until dose level 7 when the load increased to 900 mg." | 6.94 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI, 2020) |
| "Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability." | 6.90 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Holland, EC; Kaley, TJ; Lassman, AB; Mellinghoff, IK; Nolan, C; Panageas, KS, 2019) |
| "Primary glioblastoma multiforme is the most malignant form of astrocytic tumor with an average survival of approximately 12-14 months." | 5.39 | The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells. ( Fu, LS; Guo, J; Qin, LS; Sun, G; Xu, J; Yu, ZQ; Zhang, SM; Zhu, J, 2013) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 5.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Erucylphosphocholine (ErPC) is a promising antineoplastic drug for the treatment of malignant brain tumors." | 5.32 | MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M; Otten, K, 2004) |
| "Previous ex vivo spectroscopic data from tissue samples revealed differences in phospholipid metabolites between isocitrate dehydrogenase mutated (IDHmut) and IDH wildtype (IDHwt) gliomas." | 3.91 | In vivo Metabolic Profiles as Determined by ( Bähr, O; Franz, K; Hattingen, E; Pilatus, U; Steinbach, J; Wenger, KJ, 2019) |
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 3.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 3.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| "Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study." | 3.79 | Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy. ( Banerjee, R; Joshi, N; Shanmugam, T; Thakur, A, 2013) |
| "ErPC (40 mg/kg) was given to C6 glioma-bearing rats either as a single intracarotid bolus injection in the presence or absence of 1- O-pentylglycerol (300 m M) or as an intracarotid infusion in conjunction with bradykinin." | 3.71 | Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M, 2002) |
| "The authors sought to compare 1H magnetic resonance spectroscopy (MRS) spectra from extracts of low-grade and high-grade gliomas, especially with respect to the signals of choline-containing compounds." | 3.70 | Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. ( Berry, I; Breil, S; Delisle, MB; Gilard, V; Malet-Martino, M; Manelfe, C; Ranjeva, JP; Sabatier, J; Terral, C; Tremoulet, M, 1999) |
| "In the present study we investigate the effect of exogenous sphingosine, sphingosine 1-phosphate and sphingosylphosphorylcholine on phospholipase D (PLD) activity in glioma C6 cells." | 3.70 | Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells. ( Barańska, J; Bobeszko, M; Dygas, A; Sidorko, M, 1999) |
| "The effect of sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate on L-[U-14C]serine incorporation into phosphatidylserine and phosphatidylserine-derived phosphatidylethanolamine was investigated in intact glioma C6 cells." | 3.70 | Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells. ( Barańska, J; Wójcik, M, 1999) |
| "Perifosine was fixed as a 600 mg load on day 1 followed by 100 mg nightly (single agent MTD) until dose level 7 when the load increased to 900 mg." | 2.94 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI, 2020) |
| "Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability." | 2.90 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Holland, EC; Kaley, TJ; Lassman, AB; Mellinghoff, IK; Nolan, C; Panageas, KS, 2019) |
| "Many types of cancer, for example glioblastoma, show resistance against current anti-cancer treatments." | 2.50 | Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment. ( Gavish, M; Kugler, W; Veenman, L, 2014) |
| "Glioblastoma is a highly malignant brain tumor that relentlessly defies therapy." | 2.47 | Genetics of glioblastoma: a window into its imaging and histopathologic variability. ( Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA, 2011) |
| "Glycine was detected in 24% of all studies, though with a wide range of signal amplitude and extent of the spatial distributions." | 1.40 | Mapping of glycine distributions in gliomas. ( Behari, S; Gupta, RK; Hussain, N; Maudsley, AA; Parra, NA; Roy, B; Sheriff, S; Stoyanova, R, 2014) |
| "Primary glioblastoma multiforme is the most malignant form of astrocytic tumor with an average survival of approximately 12-14 months." | 1.39 | The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells. ( Fu, LS; Guo, J; Qin, LS; Sun, G; Xu, J; Yu, ZQ; Zhang, SM; Zhu, J, 2013) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 1.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Erucylphosphocholine (ErPC) is a promising antineoplastic drug for the treatment of malignant brain tumors." | 1.32 | MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M; Otten, K, 2004) |
| "Eighty-five brain metastases in 81 patients were investigated before treatment and 16-18h thereafter." | 1.32 | Early metabolic changes in metastatic brain tumors after Gamma Knife radiosurgery: 1H-MRS study. ( Abe, K; Chernov, MF; Hayashi, M; Hori, T; Izawa, M; Kubo, O; Ono, Y; Usukura, M, 2004) |
| "Erucylphosphocholine (ErPC) is a promising candidate for the treatment of human brain tumors." | 1.31 | Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. ( Eibl, H; Erdlenbruch, B; Hammersen, K; Jendrossek, V; Krügener, R; Kugler, W; Lakomek, M, 2002) |
| "Choline was elevated in the cellular portion of both tumors but decreased in the necrotic or cystic portions." | 1.29 | Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. ( Booth, RA; Buchthal, SD; Chang, L; Cornford, M; Ernst, TM; Jenden, D; McBride, D; Miller, BL, 1995) |
| "The pH of brain tumors (7." | 1.28 | P-31 MR spectroscopy of normal human brain and brain tumors. ( Hubesch, B; Matson, GB; Meyerhoff, DJ; Roth, K; Sappey-Marinier, D; Weiner, MW, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (19.05) | 18.2507 |
| 2000's | 13 (30.95) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 4 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, H | 1 |
| Chao, Y | 1 |
| Zhao, H | 1 |
| Zhou, X | 1 |
| Zhang, F | 1 |
| Zhang, Z | 1 |
| Li, Z | 2 |
| Pan, J | 1 |
| Wang, J | 1 |
| Chen, Q | 1 |
| Liu, Z | 1 |
| Sandbhor, P | 1 |
| Goda, JS | 1 |
| Mohanty, B | 1 |
| Chaudhari, P | 1 |
| Dutt, S | 1 |
| Banerjee, R | 2 |
| Kaley, TJ | 2 |
| Panageas, KS | 2 |
| Pentsova, EI | 1 |
| Mellinghoff, IK | 2 |
| Nolan, C | 2 |
| Gavrilovic, I | 1 |
| DeAngelis, LM | 2 |
| Abrey, LE | 2 |
| Holland, EC | 3 |
| Omuro, A | 1 |
| Lacouture, ME | 1 |
| Ludwig, E | 1 |
| Lassman, AB | 2 |
| Ban, J | 1 |
| Li, S | 1 |
| Zhan, Q | 1 |
| Li, X | 1 |
| Xing, H | 1 |
| Chen, N | 1 |
| Long, L | 2 |
| Hou, X | 1 |
| Zhao, J | 1 |
| Yuan, X | 2 |
| Wang, N | 1 |
| Sun, P | 1 |
| Lv, M | 1 |
| Tong, G | 1 |
| Jin, X | 1 |
| Zhu, X | 1 |
| Al-Saffar, NMS | 1 |
| Agliano, A | 1 |
| Marshall, LV | 1 |
| Jackson, LE | 1 |
| Balarajah, G | 1 |
| Sidhu, J | 1 |
| Clarke, PA | 1 |
| Jones, C | 1 |
| Workman, P | 1 |
| Pearson, ADJ | 1 |
| Leach, MO | 1 |
| Wenger, KJ | 1 |
| Hattingen, E | 1 |
| Franz, K | 1 |
| Steinbach, J | 1 |
| Bähr, O | 1 |
| Pilatus, U | 1 |
| Ward, SM | 1 |
| Skinner, M | 1 |
| Saha, B | 1 |
| Emrick, T | 1 |
| Han, L | 1 |
| Liu, C | 1 |
| Qi, H | 1 |
| Zhou, J | 1 |
| Wen, J | 1 |
| Wu, D | 1 |
| Xu, D | 1 |
| Qin, M | 1 |
| Ren, J | 1 |
| Wang, Q | 1 |
| Liu, Y | 1 |
| Chen, I | 1 |
| Lu, Y | 1 |
| Kang, C | 1 |
| Gavrilovic, IT | 1 |
| Qin, LS | 1 |
| Yu, ZQ | 1 |
| Zhang, SM | 1 |
| Sun, G | 1 |
| Zhu, J | 1 |
| Xu, J | 1 |
| Guo, J | 1 |
| Fu, LS | 1 |
| Maudsley, AA | 1 |
| Gupta, RK | 1 |
| Stoyanova, R | 1 |
| Parra, NA | 1 |
| Roy, B | 1 |
| Sheriff, S | 1 |
| Hussain, N | 1 |
| Behari, S | 1 |
| Veenman, L | 2 |
| Gavish, M | 2 |
| Kugler, W | 7 |
| Swanson, KI | 2 |
| Clark, PA | 1 |
| Zhang, RR | 2 |
| Kandela, IK | 1 |
| Farhoud, M | 1 |
| Weichert, JP | 2 |
| Kuo, JS | 2 |
| Ríos-Marco, P | 1 |
| Ríos, A | 1 |
| Jiménez-López, JM | 1 |
| Carrasco, MP | 1 |
| Marco, C | 1 |
| Hall, LT | 1 |
| Alten, J | 1 |
| Linnemannstöns, K | 1 |
| Shandalov, Y | 1 |
| Zeno, S | 1 |
| Lakomek, M | 6 |
| Aki, A | 1 |
| Nair, BG | 1 |
| Morimoto, H | 1 |
| Kumar, DS | 1 |
| Maekawa, T | 1 |
| Oh, DY | 1 |
| Nakamura, K | 1 |
| Thiele, CJ | 1 |
| Belden, CJ | 1 |
| Valdes, PA | 1 |
| Ran, C | 1 |
| Pastel, DA | 1 |
| Harris, BT | 1 |
| Fadul, CE | 1 |
| Israel, MA | 1 |
| Paulsen, K | 1 |
| Roberts, DW | 1 |
| Thakur, A | 1 |
| Joshi, N | 1 |
| Shanmugam, T | 1 |
| Jendrossek, V | 5 |
| Hammersen, K | 1 |
| Erdlenbruch, B | 5 |
| Krügener, R | 1 |
| Eibl, H | 5 |
| Lehtimäki, KK | 1 |
| Valonen, PK | 1 |
| Griffin, JL | 1 |
| Väisänen, TH | 1 |
| Gröhn, OH | 1 |
| Kettunen, MI | 1 |
| Vepsäläinen, J | 1 |
| Ylä-Herttuala, S | 1 |
| Nicholson, J | 1 |
| Kauppinen, RA | 1 |
| Naumann, U | 1 |
| Wischhusen, J | 1 |
| Weit, S | 1 |
| Rieger, J | 1 |
| Wolburg, H | 1 |
| Massing, U | 1 |
| Weller, M | 1 |
| Otten, K | 1 |
| Albers, MJ | 1 |
| Krieger, MD | 1 |
| Gonzalez-Gomez, I | 1 |
| Gilles, FH | 1 |
| McComb, JG | 1 |
| Nelson, MD | 1 |
| Blüml, S | 1 |
| Chernov, MF | 1 |
| Hayashi, M | 1 |
| Izawa, M | 1 |
| Abe, K | 1 |
| Usukura, M | 1 |
| Ono, Y | 1 |
| Kubo, O | 1 |
| Hori, T | 1 |
| Loening, NM | 1 |
| Chamberlin, AM | 1 |
| Zepeda, AG | 1 |
| Gonzalez, RG | 2 |
| Cheng, LL | 2 |
| Momota, H | 1 |
| Nerio, E | 1 |
| de la Peña, L | 1 |
| Burgan, WE | 1 |
| Carter, DJ | 1 |
| Hollingshead, MG | 1 |
| Satyamitra, M | 1 |
| Camphausen, K | 1 |
| Tofilon, PJ | 1 |
| Chang, L | 2 |
| McBride, D | 2 |
| Miller, BL | 2 |
| Cornford, M | 2 |
| Booth, RA | 1 |
| Buchthal, SD | 1 |
| Ernst, TM | 1 |
| Jenden, D | 1 |
| Booth, R | 1 |
| Ernst, T | 1 |
| Nikas, D | 1 |
| Jenden, DJ | 1 |
| Hunold, A | 1 |
| Sabatier, J | 1 |
| Gilard, V | 1 |
| Malet-Martino, M | 1 |
| Ranjeva, JP | 1 |
| Terral, C | 1 |
| Breil, S | 1 |
| Delisle, MB | 1 |
| Manelfe, C | 1 |
| Tremoulet, M | 1 |
| Berry, I | 1 |
| Dygas, A | 1 |
| Sidorko, M | 1 |
| Bobeszko, M | 1 |
| Barańska, J | 2 |
| Wójcik, M | 1 |
| Anthony, DC | 1 |
| Comite, AR | 1 |
| Black, PM | 1 |
| Tzika, AA | 1 |
| Son, BC | 1 |
| Kim, MC | 1 |
| Choi, BG | 1 |
| Kim, EN | 1 |
| Baik, HM | 1 |
| Choe, BY | 1 |
| Naruse, S | 1 |
| Kang, JK | 1 |
| Zeller, WJ | 1 |
| Bauer, S | 1 |
| Remmele, T | 1 |
| Wowra, B | 1 |
| Sturm, V | 1 |
| Stricker, H | 1 |
| Hubesch, B | 1 |
| Sappey-Marinier, D | 1 |
| Roth, K | 1 |
| Meyerhoff, DJ | 1 |
| Matson, GB | 1 |
| Weiner, MW | 1 |
2 reviews available for phosphorylcholine and Brain Neoplasms
| Article | Year |
|---|---|
Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Membrane; Erucic Acids; Glioblastom | 2014 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell S | 2011 |
2 trials available for phosphorylcholine and Brain Neoplasms
| Article | Year |
|---|---|
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma | 2020 |
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Ne | 2019 |
38 other studies available for phosphorylcholine and Brain Neoplasms
| Article | Year |
|---|---|
Smart Nanomedicine to Enable Crossing Blood-Brain Barrier Delivery of Checkpoint Blockade Antibody for Immunotherapy of Glioma.
Topics: Animals; Antibodies; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Glioma; Immunotherapy; | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
PMPC Modified PAMAM Dendrimer Enhances Brain Tumor-Targeted Drug Delivery.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dendrimers; Doxorubicin; Drug Carri | 2021 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor | 2017 |
In vivo Metabolic Profiles as Determined by
Topics: Adult; Aged; Analysis of Variance; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Diagnosis, Diffe | 2019 |
Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Compoundin | 2018 |
Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy.
Topics: Acetylcholine; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain; B | 2019 |
The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Membrane Permeability; Cell Proliferation; Cell Survival | 2013 |
Mapping of glycine distributions in gliomas.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain; Brain Mapping; Brain Neoplasms; Choline; Diffusion Magn | 2014 |
Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection.
Topics: Aminolevulinic Acid; Animals; Brain Neoplasms; Flow Cytometry; Fluorescent Dyes; Glioma; Heterograft | 2015 |
Cholesterol homeostasis and autophagic flux in perifosine-treated human hepatoblastoma HepG2 and glioblastoma U-87 MG cell lines.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Cholesterol; Glioblastoma; Hepatoblastoma; Homeostasis | 2015 |
Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies.
Topics: Antineoplastic Agents; Brain Neoplasms; Disease Management; Glioblastoma; Humans; Multimodal Imaging | 2016 |
Potential involvement of F0F1-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines : a mechanism for induction of apoptosis via the 18 kDa mitochondrial translocat
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Butylated Hydroxyanisole; | 2010 |
Label-free determination of the number of biomolecules attached to cells by measurement of the cell's electrophoretic mobility in a microchannel.
Topics: Antibodies; Brain Neoplasms; Cell Biology; Cell Line, Tumor; Dimethylpolysiloxanes; Electrophoresis; | 2010 |
Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Drug Resistance, Neoplasm; Eto | 2011 |
Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cell | 2013 |
Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Cell Survival | 2002 |
Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Glycerol; Injec | 2002 |
Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death as studied by 1H NMR spectroscopy in vivo, ex vivo, and in vitro.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Choline; Diffusion; Ganciclovir; Genet | 2003 |
Alkylphosphocholine-induced glioma cell death is BCL-X(L)-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; bcl-X Protein; Brain Neoplasms; Caspases; Cell Line, T | 2004 |
MAP kinase pathways involved in glioblastoma response to erucylphosphocholine.
Topics: Brain Neoplasms; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Glioblastoma; Human | 2004 |
Proton-decoupled 31P MRS in untreated pediatric brain tumors.
Topics: Brain; Brain Neoplasms; Case-Control Studies; Child; Choline; Creatine; Ethanolamines; Female; Glyce | 2005 |
Early metabolic changes in metastatic brain tumors after Gamma Knife radiosurgery: 1H-MRS study.
Topics: Aged; Aspartic Acid; Brain Neoplasms; Creatine; Female; Glycerylphosphorylcholine; Humans; Lactic Ac | 2004 |
Quantification of phosphocholine and glycerophosphocholine with 31P edited 1H NMR spectroscopy.
Topics: Biomarkers, Tumor; Brain Chemistry; Brain Neoplasms; Glycerylphosphorylcholine; Humans; Molecular St | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Combined Modality Therapy; Female; Glioma; Humans; Immunohistoc | 2006 |
Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors.
Topics: Adult; Brain Neoplasms; Choline; Creatine; Female; Glycerylphosphorylcholine; Humans; Hydrogen; Lact | 1995 |
In vivo 1H MRS choline: correlation with in vitro chemistry/histology.
Topics: Brain; Brain Neoplasms; Choline; Gas Chromatography-Mass Spectrometry; Glycerylphosphorylcholine; Hu | 1996 |
Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain; Brain Neoplasms; DNA Fragment | 1999 |
Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Choline; Female; Glioma; Humans; In Vitro Techniques; Magnetic Resonan | 1999 |
Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells.
Topics: Brain Neoplasms; Enzyme Activation; Glioma; Lysophospholipids; Phospholipase D; Phosphorylcholine; S | 1999 |
Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells.
Topics: Brain Neoplasms; Glioma; Homeostasis; Lysophospholipids; Phosphorylcholine; Sphingosine; Tumor Cells | 1999 |
Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy.
Topics: Adult; Biopsy; Brain Neoplasms; Choline; Glioblastoma; Gliosis; Humans; Lactates; Lipids; Magnetic R | 2000 |
Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy.
Topics: Adult; Aspartic Acid; Biopsy, Needle; Brain; Brain Neoplasms; Creatine; Diagnosis, Differential; Ene | 2001 |
Induction of differentiation and tetraploidy by long-term treatment of C6 rat glioma cells with erucylphosphocholine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Differentiation; Cell D | 2001 |
Interstitial chemotherapy of experimental gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Screening Assays, Antitumor; Gl | 1990 |
P-31 MR spectroscopy of normal human brain and brain tumors.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain; Brain Neoplasms; Female; Humans; Image Processing, Comp | 1990 |